Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical treatments for metabolic and cardiovascular disease, central nervous system disease, respiratory and immunology, oncology, and general medicine areas. It offers products for the treatment of type II diabetes, hypertension, insomnia, Alzheimer’s-type dementia, hyperuricemia and gout, peptic ulcer, acid reflux, multiple myeloma, prostate and breast cancer, endometriosis, cancer, malignant lymphoma, and major depressive disorder diseases. The company was founded in 1998 and is based in Deerfield, Illinois. It has business and sales operations in Europe, the Russian Federation, CIS, Japan, North America, Latin America, Asia,...
One Takeda Parkway
Deerfield, IL 60015
Founded in 1998
Takeda Pharmaceuticals U.S.A., Inc. Presents at BIO International Conference 2017, Jun-21-2017 01:45 PM
May 27 17
Takeda Pharmaceuticals U.S.A., Inc. Presents at BIO International Conference 2017, Jun-21-2017 01:45 PM. Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Isabel Torres, Global Head of Access to Medicines.
Takeda Pharmaceuticals Presents at BIO International Conference 2017, Jun-20-2017 10:45 AM
May 25 17
Takeda Pharmaceuticals Presents at BIO International Conference 2017, Jun-20-2017 10:45 AM. Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Andrew Plump, Chief Medical Officer and Chief Scientific Officer.
Takeda Pharmaceuticals U.S.A., Inc. Presents Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting
Oct 17 16
Takeda Pharmaceuticals U.S.A., Inc. announced data highlighting the effectiveness and safety profile of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas, Nevada. Eleven Takeda-sponsored posters, including several vedolizumab studies featuring real-world data, as well as treatment persistence and post-marketing safety data, are being presented during the meeting. A presentation entitled 'Systematic Literature Review of Real World Effectiveness and Safety of Vedolizumab in Adult Ulcerative Colitis and Crohn's Disease Patients' (Demuth D, Bovens S, Solaman A, Curtis R, O'Byrne S, Khalid JM) examined reports describing more than 7,700 patients with moderate-to-severely active UC or CD receiving treatment with vedolizumab. Investigators analyzed treatment benefit and safety profile with vedolizumab from their review of patients with moderately to severely active UC or CD. Additional real-world vedolizumab data will be presented at ACG, including poster presentations entitled 'Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab vs. Infliximab in the United States'(Khalid JM, Raluy-Callado M, Li Q, Luo M, Lasch K) and 'Hospitalizations and Treatment Discontinuation Among Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab Compared with Infliximab'(Khalid JM, Raluy-Callado M, Alam N, Wang R). Included among Takeda's other vedolizumab presentations at ACG are two abstracts focusing on real-world treatment persistence, entitled 'Real World Treatment Persistence with Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease: A Retrospective Claims Analysis in the U.S.' (Null KD, Visaria J, Demuth D, et al.) and 'Real-World Treatment Persistence with Vedolizumab in Crohn's Disease and Ulcerative Colitis Patients in the United States (US): A Retrospective Analysis Using the Optum Research Database' (Demuth D, Patel H, Chastek B, Lee B, Khalid JM, Null KD). Vedolizumab is approved as a humanized monoclonal antibody under the trade name Entyvio® (vedolizumab). It is the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha antagonist. Entyvio, an integrin receptor antagonist, is a humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks the interaction of alpha4beta7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Entyvio does not bind to or inhibit function of the alpha4beta1 and alpha E beta 7 integrins and does not antagonize the interaction of alpha4 integrins with vascular cell adhesion molecule-1 (VCAM-1). The alpha4beta7 integrin is expressed on the surface of a discrete subset of memory T-lymphocytes that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T-lymphocytes to gut lymph tissue. The interaction of the alpha4beta7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn's disease. ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for inducing and maintaining clinical response, inducing and maintaining clinical remission, improving endoscopic appearance of the mucosa, and achieving corticosteroid-free remission. ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission. ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients. Infusion-related reactions and hypersensitivity reactions including anaphylaxis have occurred. Allergic reactions including dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have also been observed. If anaphylaxis or other serious allergic reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment. Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberc ulosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice. Although no cases of PML have been observed in ENTYVIO clinical trials, JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death has occurred in patients treated with another integrin receptor antagonist. A risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.